Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Thatcher

Showing results (181-190 of 289) with videos related to

Pageof 29
Sort By:
British Journal of Cancer|September 1, 1985
Three months treatment with chemotherapy and radiotherapy for small cell lung cancerN Thatcher, R Stout, D B Smith, et al.
British Journal of Cancer|August 1, 1986
Expression of epidermal growth factor receptor (EGF-R) in human lung tumoursT Cerny, D M Barnes, P Hasleton, et al.
Leukemia|November 11, 1999
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapyN Chinnasamy, J Rafferty, L Lashford, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancerM J Lind, S Gomm, A P Simmonds, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.
British Journal of Cancer|June 1, 1995
Volunteers or victims: patients' views of randomised cancer clinical trialsM Slevin, J Mossman, A Bowling, et al.
British Journal of Cancer|February 1, 1991
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II studyS A Gomm, N Thatcher, A Cuthbert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Biochemical Pharmacology|June 1, 1989
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivoM J Lind, A T McGown, J A Hadfield, et al.
Seminars in Oncology|May 13, 1998
Dose intensity in small cell lung cancerN Thatcher, S M Lee, P J Woll, et al.
Pageof 29

Showing results (181-190 of 289) with videos related to

Sort By:
Pageof 29
British Journal of Cancer|September 1, 1985
Three months treatment with chemotherapy and radiotherapy for small cell lung cancerN Thatcher, R Stout, D B Smith, et al.
British Journal of Cancer|August 1, 1986
Expression of epidermal growth factor receptor (EGF-R) in human lung tumoursT Cerny, D M Barnes, P Hasleton, et al.
Leukemia|November 11, 1999
Protection of committed murine haemopoietic progenitors against BCNU toxicity does not predict protection of primitive, multipotent spleen colony-forming cells - implications for chemoprotective gene therapyN Chinnasamy, J Rafferty, L Lashford, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1991
A phase II study of ifosfamide and a2b-interferon in advanced non-small-cell lung cancerM J Lind, S Gomm, A P Simmonds, et al.
European Journal of Cancer (Oxford, England : 1990)|July 20, 2005
A phase II trial with RFS2000 (rubitecan) in patients with advanced non-small cell lung cancerS Baka, M Ranson, P Lorigan, et al.
British Journal of Cancer|June 1, 1995
Volunteers or victims: patients' views of randomised cancer clinical trialsM Slevin, J Mossman, A Bowling, et al.
British Journal of Cancer|February 1, 1991
High dose combination chemotherapy with ifosfamide, cyclophosphamide or cisplatin, mitomycin C and mustine with autologous bone marrow support in advanced non-small cell lung cancer. A phase I/II studyS A Gomm, N Thatcher, A Cuthbert, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1990
The stability of ifosfamide in aqueous solution and its suitability for continuous 7-day infusion by ambulatory pumpJ A Radford, J M Margison, R Swindell, et al.
Biochemical Pharmacology|June 1, 1989
The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivoM J Lind, A T McGown, J A Hadfield, et al.
Seminars in Oncology|May 13, 1998
Dose intensity in small cell lung cancerN Thatcher, S M Lee, P J Woll, et al.
Pageof 29